acute lymphoblastic leukemia, in relapse

Showing 1 - 25 of 26

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

Determining the Mechanisms of Loss of CAR T Cell Persistence

Not yet recruiting
  • Acute Lymphoblastic Leukemia With Failed Remission
  • +4 more
    • (no location specified)
    Mar 29, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CD19 specific Chimeric Antigen Receptor T Cell
    • Columbus, Ohio
      Nationwide Children's Hospital
    Mar 9, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +4 more
    • Utrecht, Netherlands
      Princess Máxima Center for Pediatric Oncology
    Feb 16, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +4 more
    • Utrecht, Netherlands
      Princess Máxima Center for Pediatric Oncology
    Feb 22, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • São Paulo, Brazil
      Hospital Israelita Albert Einstein
    Jan 20, 2023

    MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)

    Recruiting
    • Myelodysplastic Syndromes, de Novo
    • +10 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Jan 23, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Trial in Memphis (drug, device, biological)

    Active, not recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • Acute Lymphoblastic Leukemia, Refractory
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Jan 3, 2023

    Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent,

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +4 more
    • Utrecht, Netherlands
      Princess Máxima Center for Pediatric Oncology
    Dec 13, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
    • +4 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin
    Sep 22, 2022

    Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia Trial in Beijing

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +2 more
    • chimeric antigen receptor T cell
    • Beijing, Beijing, China
      Beijing Boren Hospital
    Aug 12, 2022

    Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Beijing

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +2 more
    • Autologous humanized anti-CD22 chimeric antigen receptor T cells
    • Beijing, Beijing, China
      Beijing Boren Hospital
    Aug 12, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +2 more
    • CD19-CAR(Mem) T-cells
    • +5 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Aug 5, 2022

    B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse Trial (Decreasing starting times for beginning

    Not yet recruiting
    • B Acute Lymphoblastic Leukemia
    • Acute Lymphoblastic Leukemia, in Relapse
    • Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )
    • Nivolumab starting at day -1
    • (no location specified)
    Apr 4, 2022

    Acute Lymphoblastic Leukemia, in Relapse Trial in Bergamo, Monza (CARCIK-CD19)

    Active, not recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • CARCIK-CD19
    • Bergamo, BG, Italy
    • +1 more
    Feb 3, 2022

    Acute Lymphoblastic Leukemia, in Relapse Trial in Belgium, France (GRASPA, L-asparaginase)

    Completed
    • Acute Lymphoblastic Leukemia, in Relapse
    • Bruxelles, Belgium
    • +27 more
    Feb 1, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease Trial in Mexico City (Bortezomib)

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +2 more
    • Mexico City, Mexico
      Hospital General de México "Dr. Eduardo Liceaga"
    Jan 2, 2022

    Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse Trial in Italy (Ponatinib)

    Recruiting
    • Philadelphia-Positive ALL
    • Acute Lymphoblastic Leukemia, in Relapse
    • Ancona, Italy
    • +21 more
    Jan 3, 2022

    Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, in Relapse Trial in Moscow (boost

    Recruiting
    • Acute Myeloid Leukemia
    • +6 more
    • boost anti-viral immunity after T-cell depleted HSCT
    • Moscow, Russian Federation
      Federal Research Center for pediatric hematology, oncology and i
    Oct 1, 2021

    Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia Trial in Wuhan (pCAR-19B cells)

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • Refractory Acute Lymphoblastic Leukemia
    • pCAR-19B cells
    • Wuhan, Hubei, China
      Tongji Hospital affiliated to Tongji Medical College of Huazhong
    May 12, 2021

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic

    Unknown status
    • Acute Lymphoblastic Leukemia, in Relapse
    • +2 more
    • CD19-CAR-T2 Cells
    • Guangzhou, Guangdong, China
      Nanfang Hospital, Southern Medical University
    Oct 25, 2020

    Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse Trial in Hangzhou (CD19/BCMA

    Recruiting
    • Multiple Myeloma in Relapse
    • +5 more
    • CD19/BCMA Targeted CAR T-cells and dasatinib
    • CD19/BCMA Targeted CAR T-cells
    • Hangzhou, Zhejiang, China
      The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
    Oct 27, 2020

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in Memphis (Palbociclib Oral

    Terminated
    • Acute Lymphoblastic Leukemia, in Relapse
    • Acute Lymphoblastic Leukemia With Failed Remission
    • Palbociclib Oral Capsule
    • +6 more
    • Memphis, Tennessee
      St. Jude Children's Research Hospital
    Aug 28, 2020

    Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapse Trial in

    Unknown status
    • Acute Lymphoblastic Leukemia Recurrent
    • +4 more
    • INA03 administration
    • Marseille, Bouches-du Rhône, France
    • +1 more
    Feb 4, 2020